IMABGEN Project, an innovative platform in immunotherapies

Lyon, December 16, 2021

The IMABGEN Platform project, an innovative service for the generation of therapeutic antibodies carried by BIOTEM, CALIXAR and the CNRS / Université Claude Bernard Lyon 1, is one of the laureates of the ‘‘R&D Booster’’ 2021 program driven by the Region Auvergne-Rhône-Alpes.

Immunotherapy has become a major approach in the fight against cancer. One of its modes of action – a discovery awarded the 2018 Nobel Prize – uses antibodies that bind very specifically to cellular antigens, thereby modulating or neutralizing their function. The prolongation of the success of this therapeutic route, by acting on new targets, is however closely linked to the ability to isolate new high-performance antibodies, as well as to the preservation of the structure of the antigens which condition their interaction.

Read the full press release

Press Contacts:
For CNRS: Sébastien Buthion, CNRS Rhône Auvergne Communication dr07.communication@cnrs.fr
+33 688 618 896
For BIOTEM: Jonathan Mayali, BIOTEM Communication
info@biotem.fr
+33 476 939 735
For CALIXAR: Claire Troillard, CALIXAR Communication
contact@calixar.com
+33 481 076 460

Research Contacts:
Pierre Falson, Research Director CNRS
pierre.falson@ibcp.fr
Jean-Michel Jault, Research Director CNRS
jean-michel.jault@ibcp.fr

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *